DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder
Open Access
- 4 October 2018
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (10), 3026
- https://doi.org/10.3390/ijms19103026
Abstract
So far, genetic studies of treatment response in schizophrenia, bipolar disorder, and major depression have returned results with limited clinical utility. A gene × environment interplay has been proposed as a factor influencing not only pathophysiology but also the treatment response. Therefore, epigenetics has emerged as a major field of research to study the treatment of these three disorders. Among the epigenetic marks that can modify gene expression, DNA methylation is the best studied. We performed a systematic search (PubMed) following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA guidelines for preclinical and clinical studies focused on genome-wide and gene-specific DNA methylation in the context of schizophrenia, bipolar disorders, and major depressive disorder. Out of the 112 studies initially identified, we selected 31 studies among them, with an emphasis on responses to the gold standard treatments in each disorder. Modulations of DNA methylation levels at specific CpG sites have been documented for all classes of treatments (antipsychotics, mood stabilizers, and antidepressants). The heterogeneity of the models and methodologies used complicate the interpretation of results. Although few studies in each disorder have assessed the potential of DNA methylation as biomarkers of treatment response, data support this hypothesis for antipsychotics, mood stabilizers and antidepressants.Funding Information
- Jawaharlal Institute Of Postgraduate Medical Education and Research (JIP/Res/Intra-PhD/01/2014, IFC/4098/RCF2016/853)
This publication has 100 references indexed in Scilit:
- DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEPTranslational Psychiatry, 2013
- Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDIINeuropsychopharmacology, 2012
- Neuronal activity modifies the DNA methylation landscape in the adult brainNature Neuroscience, 2011
- Activation of Group II Metabotropic Glutamate Receptors Promotes DNA Demethylation in the Mouse BrainMolecular Pharmacology, 2011
- Database of genetic studies of bipolar disorderPsychiatric Genetics, 2011
- Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey InitiativeArchives of General Psychiatry, 2011
- Phosphatidylinositol 3-Kinase (PI3K) Signaling via Glycogen Synthase Kinase-3 (Gsk-3) Regulates DNA Methylation of Imprinted LociOnline Journal of Public Health Informatics, 2010
- Valproate and Amitriptyline Exert Common and Divergent Influences on Global and Gene Promoter-Specific Chromatin Modifications in Rat Primary AstrocytesNeuropsychopharmacology, 2009
- Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylationProceedings of the National Academy of Sciences of the United States of America, 2008
- Meta-analyses of genetic studies on major depressive disorderMolecular Psychiatry, 2007